Drug Companies ‘Just Say No’ to Psych Drugs
The market for psychiatric drugs is, of course, booming. In 2011, spending on psychiatric medications can expect to top $40 billion. Yet, in spite...
”Broken Brains” and “Beautiful Minds”
When I first interviewed Brandon Banks, in the spring of 2008, while researching Anatomy of an Epidemic, he had recently entered Elizabethtown Community College...
Update on the Star*D Report
Two months ago, I wrote a post about a New Yorker article that reported that 67% of the depressed patients in the STAR*D trial...
A Schizophrenia Mystery Solved?
One of the enduring mysteries in schizophrenia research circles has been the disparity in outcomes between schizophrenia patients in "developing countries" and those in...
Antipsychotics/Schizophrenia
The long-term outcomes literature for antipsychotics, which has been compiled over a period of nearly 50 years, consistently tells of drugs that increase the...
Fact Checking the New Yorker, Part Two
In his March 1 article in the New Yorker, Louis Menand wrote that the NIMH's STAR*D trial showed that antidepressants produced a 67% recovery...
Fact Checking the New Yorker
In the March 1 issue of the New Yorker, Louis Menand surveyed the topsy-turvy world of treatments for depression, writing in part of the...
